Table 1.
Baseline demographic and clinical characteristics
| Acute myocardial infarction | Peripheral arterial disease | Heart failure | Arrhythmias | Cardiac arrest | All-cause mortality | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | |
| n | 10 132 | 202 125 | 743 | 14 793 | 18 903 | 376 633 | 3363 | 67 166 | 1519 | 30 274 | 54 588 | 1 083 341 |
| Person years of follow-up | 22 578 | 450 069 | 1550 | 30 833 | 40 855 | 814 073 | 7569 | 151 169 | 3384 | 67 836 | 121 696 | 2 413 660 |
| Male (%) | 67.9 | 67.9 | 66.8 | 66.7 | 65.3 | 65.3 | 68.6 | 68.6 | 73.3 | 73.2 | 66.3 | 66.4 |
| Age (years) (mean±SD) | 80.6 ± 4.8 | 80.6 ± 4.8 | 79.9 ± 4.6 | 79.8 ± 4.6 | 81.1 ± 5.0 | 81.1 ± 4.9 | 79.3 ± 4.7 | 79.3 ± 4.7 | 80.4 ± 4.7 | 80.4 ± 4.6 | 82.0 ± 5.3 | 81.9 ± 5.1 |
| Morbidities (%) | ||||||||||||
| Diabetes | 15.5 | 8.6 | 13.9 | 8.5 | 16.6 | 7.8 | 13.9 | 8.8 | 17.8 | 9.0 | 12.0 | 7.4 |
| Obesity | 1.0 | 0.5 | 1.5 | 0.6 | 1.4 | 0.5 | 1.5 | 0.6 | 1.3 | 0.6 | 0.9 | 0.5 |
| Dementia | 4.2 | 3.8 | 3.8 | 3.5 | 4.3 | 3.8 | 3.2 | 3.3 | 6.0 | 4.0 | 10.3 | 2.8 |
| Hypertension | 24.9 | 17.0 | 30.1 | 17.7 | 27.0 | 16.2 | 28.5 | 17.8 | 31.2 | 18.2 | 42.6 | 53.5 |
| Ischaemic heart disease | 25.3 | 12.4 | 28.1 | 13.5 | 26.0 | 11.8 | 29.6 | 13.5 | 29.0 | 14.3 | 31.7 | 36.8 |
| Respiratory diseases | 12.2 | 7.0 | 11.7 | 7.2 | 15.9 | 6.2 | 15.8 | 7.2 | 17.0 | 7.8 | 12.6 | 4.9 |
| Liver disease | 0.2 | 0.1 | 0.0 | 0.1 | 0.3 | 0.1 | 0.4 | 1.4 | 0.4 | 0.1 | 0.5 | 0.1 |
| Rheumatoid arthritis | 0.2 | 0.1 | 0.0 | 0.1 | 0.4 | 0.1 | 0.5 | 0.2 | 0.5 | 0.2 | 0.7 | 0.1 |
| Renal failure | 7.6 | 2.9 | 8.6 | 2.8 | 8.4 | 2.3 | 7.2 | 2.9 | 9.9 | 3.4 | 10.2 | 2.5 |
| Medications (%) | ||||||||||||
| Obesity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Diabetes | 14.0 | 7.9 | 12.0 | 8.5 | 14.2 | 7.6 | 10.4 | 8.4 | 14.7 | 8.2 | 10.5 | 7.7 |
| Anti-thrombotic | 43.1 | 35.3 | 54.6 | 35.1 | 51.9 | 34.7 | 44.4 | 35.5 | 48.8 | 36.7 | 41.8 | 36.3 |
| Cardiovascular | 81.4 | 70.4 | 84.0 | 71.0 | 87.0 | 69.6 | 83.4 | 70.6 | 84.3 | 70.7 | 72.7 | 70.6 |
| Salicylic acid and derivatives | 15.3 | 12.1 | 18.2 | 12.2 | 15.5 | 12.1 | 14.8 | 11.6 | 15.2 | 12.0 | 14.8 | 12.4 |
| Dementia | 1.6 | 2.1 | 1.2 | 2.1 | 1.7 | 2.1 | 1.4 | 2.0 | 2.2 | 2.0 | 2.8 | 2.1 |
| Obstructive airway disease | 2.7 | 16.3 | 21.8 | 16.5 | 30.6 | 15.4 | 26.4 | 16.9 | 26.7 | 16.9 | 27.4 | 15.9 |
| NSAIDs (last 2 years, %) | ||||||||||||
| No NSAIDs | 52.6 | 54.0 | 51.1 | 52.6 | 53.0 | 54.2 | 51.9 | 52.8 | 55.0 | 53.2 | 59.5 | 55.3 |
| ns-NSAIDs | 17.8 | 17.0 | 17.8 | 18.1 | 17.4 | 16.7 | 18.3 | 17.7 | 15.6 | 17.6 | 14.6 | 16.1 |
| Ox-Sul-ns-NSAIDs | 9.0 | 8.7 | 10.8 | 8.5 | 8.3 | 8.6 | 9.1 | 9.2 | 8.3 | 8.9 | 6.6 | 8.3 |
| COX-2 inhibitors | 33.7 | 31.9 | 33.2 | 33.3 | 33.5 | 32.0 | 33.8 | 32.4 | 31.3 | 32.1 | 28.5 | 31.2 |
| Any NSAID | 47.4 | 46.0 | 48.9 | 47.4 | 47.0 | 46.0 | 48.1 | 47.1 | 45.0 | 46.8 | 40.5 | 44.7 |
| Specific NSAIDs (last 2 years, %) | ||||||||||||
| Diclofenac | 6.0 | 7.8 | 8.5 | 7.9 | 7.4 | 7.7 | 8.7 | 8.2 | 6.2 | 7.9 | 6.2 | 7.4 |
| Naproxen | 2.8 | 2.7 | 3.0 | 3.2 | 3.0 | 2.8 | 2.9 | 2.9 | 2.8 | 2.9 | 2.5 | 2.7 |
| Ibuprofen | 2.7 | 2.8 | 2.8 | 2.9 | 3.1 | 2.8 | 2.8 | 2.8 | 2.9 | 3.0 | 2.7 | 2.7 |
| Meloxicam | 6.7 | 6.4 | 7.9 | 6.1 | 6.1 | 6.3 | 6.8 | 6.7 | 5.7 | 6.5 | 4.9 | 6.2 |
ns-NSAID, non-selective NSAID; Ox-Sul-ns-NSAIDs, meloxicam, piroxicam and sulindac.